NSIS B — Novozymes A/S Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsBalancedLarge CapHigh Flyer

Annual income statement for Novozymes A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	fx Final	Final	Final
Revenue
Total Revenue	2,011	2,360	2,403	3,834	4,158
Cost of Revenue
Gross Profit	1,162	1,288	1,305	1,810	2,242
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,472	1,711	1,869	3,333	3,341
Operating Profit	539	649	534	501	817
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	528	613	525	417	743
Provision for Income Taxes
Net Income After Taxes	423	496	408	306	584
Minority Interest
Net Income Before Extraordinary Items
Net Income	423	494	406	306	584
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	423	494	406	306	584
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.48	1.63	1.64	0.984	1.4
Dividends per Share